Quarterly Result10 Nov 2025, 07:42 pm
Fredun Pharmaceuticals Reports 61% YoY Growth in EBITDA to ¥39.33 Cr in H1 FY26
AI Summary
Fredun Pharmaceuticals Limited, a leading pharmaceuticals formulation manufacturing company in India, has reported its unaudited financials for Q2 FY26 & H1 FY26. The company has seen a YoY growth of 60.09% in EBITDA for H1 FY26, reaching ¥39.33 Cr. The total income for H1 FY26 stands at ¥265.15 Cr, a significant increase from H1 FY25. The net profit for Q2 FY26 is ¥9.73 Cr, a 127.75% YoY growth. The company has also reported a net profit margin of 6.70% for Q2 FY26.
Key Highlights
- Fredun Pharmaceuticals reported a YoY growth of 60.09% in EBITDA for H1 FY26, reaching ¥39.33 Cr.
- The total income for H1 FY26 stands at ¥265.15 Cr, a significant increase from H1 FY25.
- The net profit for Q2 FY26 is ¥9.73 Cr, a 127.75% YoY growth.
- The company has also reported a net profit margin of 6.70% for Q2 FY26.
- Fredun Pharmaceuticals is expanding its state-of-the-art manufacturing facility at Palghar to enhance capacity and improve operational efficiency.